Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
This grant funds research to explore innovative uses of nanotechnology in cancer biology and oncology for better cancer treatments, excluding clinical trials.
Browse similar grants
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: November 3, 2025 | May 4, 2026 (new, renewal, resubmission, revision)
Funding Amounts: Up to $475,000 in direct costs per year, for a maximum of 5 years (R01 mechanism)
Summary: Supports mechanistic, fundamental research using nanotechnology to address major barriers in cancer biology and oncology; clinical trials are not allowed.
Key Information: Projects must focus on mechanistic studies, not clinical translation; foreign organizations are not eligible to apply, but foreign components are allowed.
Description
This opportunity, offered by the National Cancer Institute (NCI) at NIH, funds innovative, multidisciplinary research that leverages nanotechnology to address significant challenges in cancer biology and oncology. The focus is on mechanistic studies that expand fundamental understanding of how nanomaterials and nanodevices interact with biological systems, particularly in the context of cancer detection, diagnosis, and therapy. The goal is to generate foundational knowledge that will inform future development of nanotechnology-based cancer interventions. Clinical trials and direct clinical translation are outside the scope of this funding.
